Samsung Biologics expands global contract development reach at PEGS Boston 2025
Samsung Biologics, the biotech arm of Samsung Group, announced Tuesday that it participated in the 2025 Protein & Antibody Engineering Summit, the world's largest academic conference on protein and antibody therapeutics, on May 12 in Boston.
During the five-day event, the company hosted a dedicated meeting room to engage with global pharmaceutical companies and expand its client network.
On March 12, Samsung Biologics held a luncheon presentation titled 'Streamlining drug development: From developability assessment to high-concentration formulation development.'
Lim Heon-chang, Director of Formulation Development at Samsung Biologics, introduced the company's proprietary platforms — S-HiCon, a high-concentration formulation platform launched in October 2024, and Developick, a developability assessment platform now in its third version.
These platforms enable more efficient biologics development, from early-stage evaluation using minimal protein samples to formulation of patient-friendly, high-concentration drugs.
Alongside S-HiCon and Developick, Samsung Biologics now offers nine specialized contract development organization platforms, including S-Choice, S-Dual and S-Tensify, covering the full CDO spectrum from discovery to investigational new drug application.
The company has actively participated in major global events such as the JPMorgan Healthcare Conference and DCAT Week, and is set to strengthen its business development efforts further at the upcoming BIO International Convention in Boston next month.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
30-05-2025
- Korea Herald
Posco opens minerals lab in Australia
Posco Holdings, the holding company of Korean steel giant Posco Group, said Friday it has opened a key minerals research center in Australia to secure a technological edge in advanced materials, spanning steelmaking, battery materials and rare earths. According to the group, the new launch underscores its commitment to localization strategies, designed to not only secure raw materials cost-effectively, but also advance low-carbon processing technologies. Located in Perth, the center will focus on developing low-carbon steelmaking and cost-reduction technologies for lithium and nickel. It will also pursue rare earths supply chain development and high-efficiency refining technologies. This marks the first time a Korean company has established an on-site resources facility at a site sourcing raw materials, the company explained. 'Since 1971, when Posco first imported Australian iron ore, the company has built strong trust and collaboration with the Australian government and industry, emerging as a global top-tier materials company in steelmaking and battery materials,' said Chair Chang In-hwa at the opening ceremony in Perth on Friday, which was attended by executives from Australian resource companies, as well as representatives from local academic and research institutions. 'This center, combining Australia's rich resources with the group's materials technology expertise, will serve as a hub for advancing mineral processing technologies and securing critical minerals,' Chang added. The new facility brings the group a step closer to the Chang's goal of integrating technology and business strategy across the full spectrum of operations, from research and development to production and sales. The group said it will continue exploring next-generation minerals and pursuing local mining investments through partnerships. Since the early 1980s, Posco has worked closely with Australian partners to build supply chains for key minerals. The company has participated in the development of the Roy Hill iron ore mine and currently operates a joint venture with Australian lithium mining company PLS to produce lithium hydroxide for secondary battery materials.
Korea Herald
29-05-2025
- Korea Herald
Spinoff or stay? Samsung's foundry dilemma back in spotlight
Experts say spinning off lackluster foundry could boost trust, competitiveness, but Samsung says it's too early Samsung Electronics is again facing speculations that it may spin off its foundry business from the broader semiconductor division, amid concerns over the same conflicts of interest that drove Samsung Biologics to split its biosimilar business and contract drug manufacturing. Last week, Samsung Biologics, the biotech arm of Samsung Group, announced it will spin off its biosimilar subsidiary Samsung Bioepis into an independent entity. Once the deal is completed, Samsung Biologics will only retain its contract development and manufacturing organization, a strategic move aimed to address growing customer and investor concerns about potential conflicts of interest in its competing business lines. A similar conflict of interest conundrum has long weighed on Samsung Electronics' Device Solution division, which houses three distinct yet interconnected semiconductor operations under one roof: memory chips, foundry and System LSI. While the foundry manufactures chips for fabless companies, System LSI is responsible for designing logic chips, including Samsung's own Exynos. This dual role as both a chip designer and a manufacturer has raised concerns over possible technology leakage and inherent conflicts of interest for years. 'Trust is critical in the foundry business," said an industry source who requested anonymity. "For fabless companies like Nvidia and Qualcomm that don't manufacture their own chips and rely on foundries, there's always concern that sensitive design data could be exposed to competitors. Spinning off the foundry business would reduce these risks and make Samsung more competitive." Growing calls for spinoff Many market analysts have been calling on Samsung to carve out its foundry unit, arguing that organizational independence would help the company respond quickly to clients' demands and scale faster to keep up with technological advancement. Even the conglomerate's financial subsidiary Samsung Securities, recommended that Samsung spin off the foundry and list on the US market in a 2022 report. The broader semiconductor industry is also moving away from integrated device manufacturer models like Samsung -- where a single company handles both chip design and manufacturing -- toward a more specialized structure such as a fabless-foundry partnership. A fellow IDM Intel is also reportedly exploring a similar path, considering spinning off its foundry unit, potentially as a joint venture with TSMC. Another factor driving the spinoff discussion is financial. Analysts say Samsung's underperforming foundry unit is dragging down Samsung Electronics' bottom line. In the first quarter of 2025, Samsung's DS division reported revenue of 25.1 trillion won ($18.17 billion) and an operating profit of 1.1 trillion won, down 42 percent on-year and marked the third consecutive quarter of decline. This figure falls far short of the 7 trillion won profit posted by smaller chipmaking rival SK hynix posted during the same period. While Samsung does not disclose performance by specific business unit, industry sources estimated that memory chip operations posted around 3 trillion won in operating profit, which was offset by 2 trillion won losses in System LSI and foundry. This sluggish performance of its non-memory chip units strengthens the argument for a spinoff, yet paradoxically, this same weakness makes near-term divestiture less feasible. Too early to split? 'In principle, Samsung's spinoff would be ideal, similar to TSMC, whose specialization in foundry services has earned trust from customers,' said Lee Jong-hwan, a system semiconductor engineering professor at Sangmyung University. 'But right now, Samsung foundry remains in the red, and splitting off under these conditions would be meaningless. The company must first return to profitability and then consider a spinoff when it's ready. It's too early for now." Given the capital-intensive nature of the foundry business, any separation would require a stable revenue stream and securing major clients, both of which Samsung currently lacks, observers say. If Samsung were to spin off its foundry unit, it would lose key advantages of operating under the umbrella of Samsung Electronics. Despite continued losses, the foundry has managed to stay afloat and conduct large-scale investments, largely due to the tech giant's strong earnings from its memory and consumer electronics businesses, including smartphones. Amid growing speculation, Samsung is not considering a spinoff of its foundry unit at this time, according to a source familiar with the matter. Even Samsung Electronics Chair Lee Jae-yong appears reluctant on the idea. 'We are hungry to grow the business. Not interested in spinning (them) off,' Lee told Reuters last October in the Philippines, when asked whether the tech giant is considering spinning off the foundry. Professor Lee noted that Samsung envisions becoming a successful IDM capable of excelling in both memory and non-memory. In an era where AI chips are reshaping the semiconductor industry, Samsung could gain a competitive edge if it can develop and produce AI critical high-bandwidth memory chips entirely in-house. "Samsung first needs approval from Nvidia for its HBM chips to become a trusted AI chip supplier," said Professor Lee. "If that happens everything changes. But until then, the priority is profitability. Only after that can a spinoff or any kind of restructuring make strategic sense."
Korea Herald
26-05-2025
- Korea Herald
Samsung Biologics hits W3tr in cumulative orders this year
Samsung Biologics, the biotech arm of Samsung Group, reported Monday that it has surpassed 3 trillion won ($2.2 billion) in cumulative contract orders for 2025, just five months into the year, following a series of major deals with global pharmaceutical firms. According to a regulatory filing, the company recently signed two new contract manufacturing organization, or CMO, deals totaling 440.5 billion won with pharmaceutical companies based in Europe and Asia. These contracts run through December 2030 and December 2033, respectively. Due to non-disclosure agreements, client names and product details were not disclosed. So far in 2025, Samsung Biologics has signed four CMO deals across the US, Europe and Asia. This achievement represents over 60 percent of its total contract value for 2024, reinforcing the company's global competitiveness. The company now counts 17 of the world's top 20 pharmaceutical companies as clients and has accumulated total orders of approximately $18.2 billion since its founding. With the recent launch of its fifth plant in April, adding 180,000 liters of capacity, Samsung Biologics has expanded its total capacity to 784,000 liters, the largest in the world. Samsung Biologics also maintains strong performance in quality control, recording a 99 percent batch success rate last year and securing 356 manufacturing approvals from global regulators as of April 2025. To expand its global presence, the company has actively participated in major industry events including JPMorgan Healthcare Conference, DCAT Week 2025 and PEGS Boston. Samsung Biologics will next join the BIO International Convention held in Boston this June to further strengthen its global partnerships.
